e-Drug3D

1683

M AMIFOSTINE


INN
AMIFOSTINE

(is an active metabolite)

cas 31098-42-7
CLASS

VARIOUS
RADIATION-PROTECTIVE AGENTS
REDUCTION OF THE CUMULATIVE RENAL TOXICITY OF CISPLATIN AND FOR THE REDUCTION OF THE TOXIC EFFECTS OF RADIATION ON NORMAL ORAL TISSUES
SCAVENGE REACTIVE OXYGEN SPECIES

ROUTE (list)

-

ATC code

V03AF05

PK parameters

Cmax 35 MICROMOLAR
t1/2 0.13 HOUR

Target

TARGET ALKALINE PHOSPHATASE

PDB
7NIZ (HUMAN 14-3-3 SIGMA IN COMPLEX WITH HUMAN ESTROGEN RECEPTOR ALPHA PEPTIDE AND LIGANDS FUSICOCCIN-A AND WR-1065)

Ligand code = UGH (link to the list of PDB complexes)

Download experimental 3D coordinates of UGH with added hydrogens

DrugCentral

Unknown

Download SDF file Ethanethiol, 2-[(3-aminopropyl)amino]-

Formula:
C5H14N2S

Calculated chemical properties:

MW 134.25
NB_atoms 8
XLogP -0.15
PSA 39.888
NB_HD 3
NB_HA 2
fsp3 1.00
Lipinski(0=no;1=yes) 1

FDA
-

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL

e-Drug3D

699

AMIFOSTINE


INN
AMIFOSTINE

(has an active metabolite)

cas 20537-88-6
CLASS

VARIOUS
RADIATION-PROTECTIVE AGENTS
PRODRUG
REDUCTION OF THE CUMULATIVE RENAL TOXICITY OF CISPLATIN AND FOR THE REDUCTION OF THE TOXIC EFFECTS OF RADIATION ON NORMAL ORAL TISSUES
INTESTINAL-TYPE ALKALINE PHOSPHATASE (IAP) IS A MAJOR ISOENZYME INVOLVED IN THE HYDROLYSIS OF AMIFOSTINE (PMID12577238)

ROUTE (list)

INJECTION

ATC code

V03AF05

PK parameters

Cmax 200 MICROMOLAR
VD 7 LITER
Cl 120 LITER / HOUR
t1/2 0.13 HOUR

Solubility

FREELY SOLUBLE IN WATER


Target

TARGET ALKALINE PHOSPHATASE

DrugCentral

Unknown

Download SDF file 2-(3-aminopropylamino)ethylsulfanylphosphonic acid

Formula:
C5H15N2O3PS

Calculated chemical properties:

MW 212.21
NB_atoms 12
XLogP -1.51
PSA 95.428
NB_HD 3
NB_HA 5
fsp3 1.00
Lipinski(0=no;1=yes) 1

FDA
NDA 020221 (label) INN (AMIFOSTINE) ETHYOL (LEGACY) APPROVAL= AP YEAR= 1995
NDA 077126 (pdf not found) INN (AMIFOSTINE) AMIFOSTINE (SUN PHARM) APPROVAL= AP YEAR= 2008 DISCONTINUED
NDA 204363 (pdf not found) INN (AMIFOSTINE) AMIFOSTINE (EUGIA PHARMA SPECLTS) APPROVAL= AP YEAR= 2017 DISCONTINUED

Other links:

PubChem
ChemicalProbes

U.S. repository of Clinical Trials

VigiAccess
SIDER side effects

ChemSynthesis
Patent@SureChEMBL